Baike Biotech announced that the company recently received the “Notice of Acceptance” of the clinical trial application for a recombinant human antirespiratory syncytial virus monoclonal antibody injection combination formulation issued by the State Drug Administration. The application is a registered clinical trial for domestically produced drugs. The acceptance number is CXSL2601038, which was accepted after review. This product is used to prevent lower respiratory tract infections caused by RSV in newborns and infants.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.